Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmitermant alfa (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions
  • Sponsors Acceleron Pharma

    • Most Recent Events

    • 16 Sep 2019 Status changed from active, no longer recruiting to discontinued, data show no evidence of such a benefit and, therefore, do not support further development of ACE-083 for FSHD, according to an Acceleron Pharma Media Release.
    • 16 Sep 2019 Results presented in an Acceleron Pharma Media Release.
    • 05 Aug 2019 According to the Acceleron Pharma media release, topline results from Part 2 of this trial are expected in the second half of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top